Valuation: Outlook Therapeutics, Inc.

Market Cap 10Cr 9.11Cr 8.43Cr 7.6Cr 14Cr 948.01Cr 15Cr 101.24Cr 40Cr 506.41Cr 38Cr 37Cr 1.61TCr P/E 2026 *
-0.71x
P/E 2027 * -1.91x
Enterprise Value 10Cr 9.11Cr 8.43Cr 7.6Cr 14Cr 948.01Cr 15Cr 101.24Cr 40Cr 506.41Cr 38Cr 37Cr 1.61TCr EV / Sales 2026 *
147x
EV / Sales 2027 * 2.28x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day-6.16%
1 week-5.36%
Current month-11.77%
1 month-17.40%
3 months-45.40%
6 months+81.06%
Current year-73.86%
1 week 0.41
Extreme 0.41015
0.5
1 month 0.41
Extreme 0.4086
0.6
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
12.85
5 years 0.16
Extreme 0.1611
42.4
10 years 0.16
Extreme 0.1611
635.2
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Director of Finance/CFO 58 01/09/2026
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Director/Board Member 50 31/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Free

Chief Financial Officer

5,00,000 0.3122%
14/08/26 Buy

Chief Executive Officer

2,02,020 0.0832%
14/08/26 Buy

Chief Executive Officer

3,03,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
-6.16%-5.36%-73.69%-95.37% 10Cr
-2.69%-0.48%+53.97%+66.82% 6.63TCr
+0.25%+3.14%+11.13%+95.69% 6.06TCr
+1.08%+2.06%+24.77%+90.49% 5.55TCr
+0.14%+2.35%+13.86%+111.94% 4.76TCr
-2.21%-2.47%+20.18%+28.81% 4.37TCr
-2.30%-10.40%+154.30%+707.36% 3.73TCr
+2.15%+1.42%+14.58%+48.71% 3.66TCr
+2.52%-3.47%+78.89%+60.93% 3.22TCr
+2.62%+5.90%-37.29%+386.59% 2.66TCr
Average -0.46%-0.49%+26.07%+150.19% 4TCr
Weighted average by Cap. -0.12%+0.20%+36.90%+153.05%

Financials

2026 *2027 *
Net sales 7L 6L 6L 5L 10L 6.44Cr 10.07L 68.74L 27.26L 3.44Cr 25.62L 25.08L 11Cr 4.41Cr 3.99Cr 3.69Cr 3.33Cr 6.28Cr 415.54Cr 6.5Cr 44Cr 18Cr 221.97Cr 17Cr 16Cr 704.6Cr
Net income -6.51Cr -5.9Cr -5.46Cr -4.92Cr -9.28Cr -613.82Cr -9.6Cr -66Cr -26Cr -327.89Cr -24Cr -24Cr -1.04TCr -4.44Cr -4.03Cr -3.72Cr -3.36Cr -6.33Cr -418.96Cr -6.56Cr -45Cr -18Cr -223.8Cr -17Cr -16Cr -710.4Cr
Net Debt - -
Projected Income Statement - Annual - Outlook Therapeutics, Inc.
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
13/26/13 $0.4130 -6.16% 30,25,431
12/26/12 $0.4401 -8.50% 24,44,691
11/26/11 $0.4810 +4.43% 23,43,048
10/26/10 $0.4606 +0.28% 10,64,528
09/26/09 $0.4593 +5.25% 19,63,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Outlook Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.4130USD
Average target price
5.025USD
Spread / Average Target
+1,116.71%
  1. Stock Market
  2. Stocks
  3. OTLK Stock